Fortress Biotech's Subsidiary Cyprium Therapeutics Sells Rare Pediatric Disease Priority Review Voucher for $205 Million

Fortress Biotech's subsidiary Cyprium Therapeutics has closed the sale of its Rare Pediatric Disease Priority Review Voucher for $205 million. The company expects to receive over $100 million in proceeds from the transaction, which will enhance its financial flexibility. Cyprium remains eligible to receive royalties and sales milestones from Sentynl Therapeutics, the company that acquired ZYCUBO, a treatment for Menkes disease. The sale of the PRV is a transformational transaction for both Cyprium and Fortress, validating their business model and paving the way for key upcoming milestones within their broad pipeline of commercial and clinical-stage assets.